ABOS
Acumen Pharmaceuticals, Inc. NASDAQ$2.48
Mkt Cap $150.2M
52w Low $0.96
57.6% of range
52w High $3.60
50d MA $2.78
200d MA $2.07
P/E (TTM)
-1.2x
EV/EBITDA
-0.8x
P/B
2.0x
Debt/Equity
0.4x
ROE
-172.3%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
0.34
50d MA
$2.78
200d MA
$2.07
Avg Volume
570.2K
About
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is h…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.50 | -0.41 | +18.0% | 2.55 | -2.7% | -11.4% | -14.1% | -7.5% | +0.0% | +5.9% | — |
| Nov 12, 2025 | AMC | -0.63 | -0.44 | +30.2% | 1.95 | -2.6% | -7.2% | -11.3% | -19.0% | -14.9% | -20.5% | — |
| Aug 12, 2025 | AMC | -0.54 | -0.68 | -25.9% | 1.26 | +0.8% | +0.8% | +11.1% | +12.7% | +13.5% | +9.5% | — |
| May 13, 2025 | AMC | -0.56 | -0.48 | +14.3% | 1.05 | +0.0% | -6.7% | -3.8% | +1.9% | +1.9% | +1.0% | — |
| Mar 27, 2025 | AMC | -0.47 | -0.62 | -31.9% | 1.23 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% | — |
| Nov 12, 2024 | AMC | -0.36 | -0.50 | -38.9% | 2.68 | +1.9% | -5.6% | -2.6% | -10.4% | -16.4% | -10.8% | — |
| Aug 13, 2024 | AMC | -0.28 | -0.34 | -21.4% | 2.77 | +0.4% | -9.0% | -6.9% | -7.2% | +2.2% | +2.2% | — |
| May 14, 2024 | AMC | -0.23 | -0.25 | -8.7% | 3.69 | +0.0% | +3.0% | +1.1% | -1.1% | +4.1% | +3.3% | — |
| Mar 26, 2024 | AMC | -0.29 | -0.29 | +0.0% | 3.75 | +0.0% | +9.3% | +8.0% | +6.9% | +1.1% | +4.3% | — |
| Nov 13, 2023 | AMC | -0.31 | -0.24 | +22.6% | 2.03 | +3.4% | +4.9% | +16.7% | +10.3% | +12.3% | +16.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26 | BTIG | Maintains | Buy → Buy | — | $2.63 | $2.56 | -2.7% | -3.0% | -14.1% | -16.7% | -10.3% | -3.0% |
| Mar 16 | BTIG | Maintains | Buy → Buy | — | $3.27 | $3.50 | +7.0% | +2.1% | -5.5% | -10.7% | -10.7% | -18.3% |
| Jan 27 | BTIG | Maintains | Buy → Buy | — | $2.08 | $2.24 | +7.7% | +30.8% | +35.1% | +34.1% | +25.0% | +24.5% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $1.58 | $1.60 | +1.3% | +5.1% | -1.9% | -1.3% | -0.6% | +7.6% |
| Aug 25 | BofA Securities | Maintains | Buy → Buy | — | $1.53 | $1.52 | -0.7% | -1.3% | -4.6% | -9.2% | -14.4% | -11.1% |
| Mar 28 | UBS | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.23 | $1.24 | +0.8% | -3.3% | -10.6% | -12.2% | -12.2% | -19.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.68 | $2.73 | +1.9% | -5.6% | -2.6% | -10.4% | -16.4% | -10.8% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.50 | $2.50 | +0.0% | -4.4% | -5.2% | -4.8% | -5.6% | -8.4% |
| Aug 15 | UBS | Maintains | Buy → Buy | — | $2.52 | $2.61 | +3.6% | +2.4% | +2.0% | +12.3% | +12.3% | +13.1% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ABOS disclosed material non-public information under Reg FD, suggesting a significant business development or event occurred that investors need to evaluate for stock impact.
Mar 26
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
ABOS announced an equity issuance, which will dilute existing shareholders' ownership percentages and could pressure the stock price unless proceeds fund significant growth initiatives.
Mar 16
Data updated apr 24, 2026 10:16am
· Source: massive.com